143 related articles for article (PubMed ID: 33443139)
1. Suppression of MET Signaling Mediated by Pitavastatin and Capmatinib Inhibits Oral and Esophageal Cancer Cell Growth.
Xu B; Muramatsu T; Inazawa J
Mol Cancer Res; 2021 Apr; 19(4):585-597. PubMed ID: 33443139
[TBL] [Abstract][Full Text] [Related]
2. Feed-forward activation of STAT3 signaling limits the efficacy of c-Met inhibitors in esophageal squamous cell carcinoma (ESCC) treatment.
Zhao D; Chen J; Wang Y; Zhang L; Zhang J; Zhang W; Fan J; Li J; Zhan Q
Mol Carcinog; 2021 Jul; 60(7):481-496. PubMed ID: 34018249
[TBL] [Abstract][Full Text] [Related]
3. A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment.
Delord JP; Argilés G; Fayette J; Wirth L; Kasper S; Siena S; Mesia R; Berardi R; Cervantes A; Dekervel J; Zhao S; Sun Y; Hao HX; Tiedt R; Vicente S; Myers A; Siu LL
Invest New Drugs; 2020 Dec; 38(6):1774-1783. PubMed ID: 32410080
[TBL] [Abstract][Full Text] [Related]
4. Omipalisib Inhibits Esophageal Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK Signaling.
Zhu DS; Dong JY; Xu YY; Zhang XT; Fu SB; Liu W
Med Sci Monit; 2020 Aug; 26():e927106. PubMed ID: 32804918
[TBL] [Abstract][Full Text] [Related]
5. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
Baltschukat S; Engstler BS; Huang A; Hao HX; Tam A; Wang HQ; Liang J; DiMare MT; Bhang HC; Wang Y; Furet P; Sellers WR; Hofmann F; Schoepfer J; Tiedt R
Clin Cancer Res; 2019 May; 25(10):3164-3175. PubMed ID: 30674502
[TBL] [Abstract][Full Text] [Related]
6. PI3Kα inhibitors sensitize esophageal squamous cell carcinoma to radiation by abrogating survival signals in tumor cells and tumor microenvironment.
Shi JJ; Xing H; Wang YX; Zhang X; Zhan QM; Geng MY; Ding J; Meng LH
Cancer Lett; 2019 Sep; 459():145-155. PubMed ID: 31173854
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo synergistic anti-tumor effect of LIN28 inhibitor and metformin in oral squamous cell carcinoma.
Chen H; Sa G; Li L; He S; Wu T
Eur J Pharmacol; 2021 Jan; 891():173757. PubMed ID: 33249080
[TBL] [Abstract][Full Text] [Related]
8. Acetyl-macrocalin B suppresses tumor growth in esophageal squamous cell carcinoma and exhibits synergistic anti-cancer effects with the Chk1/2 inhibitor AZD7762.
Wang JN; Che Y; Yuan ZY; Lu ZL; Li Y; Zhang ZR; Li N; Li RD; Wan J; Sun HD; Sun N; Puno PT; He J
Toxicol Appl Pharmacol; 2019 Feb; 365():71-83. PubMed ID: 30633885
[TBL] [Abstract][Full Text] [Related]
9. Dexrazoxane inhibits the growth of esophageal squamous cell carcinoma by attenuating SDCBP/MDA-9/syntenin-mediated EGFR-PI3K-Akt pathway activation.
Du R; Xiao N; Han L; Guo K; Li K; Chen Z; Zhang H; Zhou Z; Huang Y; Zhao X; Bian H
Sci Rep; 2024 Apr; 14(1):9167. PubMed ID: 38649770
[TBL] [Abstract][Full Text] [Related]
10. A multi-kinase inhibitor APG-2449 enhances the antitumor effect of ibrutinib in esophageal squamous cell carcinoma via EGFR/FAK pathway inhibition.
Luo QY; Zhou SN; Pan WT; Sun J; Yang LQ; Zhang L; Qiu MZ; Yang DJ
Biochem Pharmacol; 2021 Jan; 183():114318. PubMed ID: 33159967
[TBL] [Abstract][Full Text] [Related]
11. Capmatinib: First Approval.
Dhillon S
Drugs; 2020 Jul; 80(11):1125-1131. PubMed ID: 32557339
[TBL] [Abstract][Full Text] [Related]
12. Scutellarin Suppresses Patient-Derived Xenograft Tumor Growth by Directly Targeting AKT in Esophageal Squamous Cell Carcinoma.
Liu F; Zu X; Xie X; Zhang Y; Liu K; Chen H; Wang T; Bode AM; Dong Z; Kim DJ
Cancer Prev Res (Phila); 2019 Dec; 12(12):849-860. PubMed ID: 31554627
[TBL] [Abstract][Full Text] [Related]
13. OP16, a novel ent-kaurene diterpenoid, potentiates the antitumor effect of rapamycin by inhibiting rapamycin-induced feedback activation of Akt signaling in esophageal squamous cell carcinoma.
Peng KZ; Ke Y; Zhao Q; Tian F; Liu HM; Hou G; Lu Z
Biochem Pharmacol; 2017 Sep; 140():16-27. PubMed ID: 28539264
[TBL] [Abstract][Full Text] [Related]
14. MS-275 combined with cisplatin exerts synergistic antitumor effects in human esophageal squamous cell carcinoma cells.
Liu T; Guan F; Wang Y; Zhang Z; Li Y; Cui Y; Li Z; Liu H; Zhang Y; Wang Y; Ma S
Toxicol Appl Pharmacol; 2020 May; 395():114971. PubMed ID: 32217144
[TBL] [Abstract][Full Text] [Related]
15. Combined class I histone deacetylase and mTORC1/C2 inhibition suppresses the initiation and recurrence of oral squamous cell carcinomas by repressing SOX2.
Liang X; Deng M; Zhang C; Ping F; Wang H; Wang Y; Fan Z; Ren X; Tao X; Wu T; Xu J; Cheng B; Xia J
Cancer Lett; 2019 Jul; 454():108-119. PubMed ID: 30981761
[TBL] [Abstract][Full Text] [Related]
16. Promotion of ubiquitination-dependent survivin destruction contributes to xanthohumol-mediated tumor suppression and overcomes radioresistance in human oral squamous cell carcinoma.
Li M; Gao F; Yu X; Zhao Q; Zhou L; Liu W; Li W
J Exp Clin Cancer Res; 2020 May; 39(1):88. PubMed ID: 32410646
[TBL] [Abstract][Full Text] [Related]
17. Ursolic Acid Accelerates Paclitaxel-Induced Cell Death in Esophageal Cancer Cells by Suppressing Akt/FOXM1 Signaling Cascade.
Meng RY; Jin H; Nguyen TV; Chai OH; Park BH; Kim SM
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768915
[TBL] [Abstract][Full Text] [Related]
18. Combined inhibition of RNA polymerase I and mTORC1/2 synergize to combat oral squamous cell carcinoma.
Shi S; Luo H; Wang L; Li H; Liang Y; Xia J; Wang Z; Cheng B; Huang L; Liao G; Xu B
Biomed Pharmacother; 2021 Jan; 133():110906. PubMed ID: 33190037
[TBL] [Abstract][Full Text] [Related]
19. Corilagin Inhibits Esophageal Squamous Cell Carcinoma by Inducing DNA Damage and Down-Regulation of RNF8.
Qiu F; Liu L; Lin Y; Yang Z; Qiu F
Anticancer Agents Med Chem; 2019; 19(8):1021-1028. PubMed ID: 30848215
[TBL] [Abstract][Full Text] [Related]
20. The PSMD14 inhibitor Thiolutin as a novel therapeutic approach for esophageal squamous cell carcinoma through facilitating SNAIL degradation.
Jing C; Li X; Zhou M; Zhang S; Lai Q; Liu D; Ye B; Li L; Wu Y; Li H; Yue K; Chen P; Yao X; Wu Y; Duan Y; Wang X
Theranostics; 2021; 11(12):5847-5862. PubMed ID: 33897885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
